Golimumab, a Tumor Necrosis Factor Alpha (TNF-α) blocker, or placebo was administered in participants within 100 days of diagnosis of stage 3 T1D and who had at least one diabetes-related autoantibody. Here, TNF is linked to type 1 diabetes mellitus.